BR0206561A - Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto - Google Patents
Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e compostoInfo
- Publication number
- BR0206561A BR0206561A BR0206561-4A BR0206561A BR0206561A BR 0206561 A BR0206561 A BR 0206561A BR 0206561 A BR0206561 A BR 0206561A BR 0206561 A BR0206561 A BR 0206561A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- aryl
- dysfunction
- conr
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 230000004064 dysfunction Effects 0.000 title abstract 5
- 230000004112 neuroprotection Effects 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- -1 ortho Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"USO DE UM COMPOSTO, MéTODO DE TRATAMENTO OU PREVENçãO DE DISFUNçõES, USO OU MéTODO, MéTODO DE NEUROPROTEçãO E COMPOSTO". Uso de um composto da fórmula (I): em que: - R~ 1~, é selecionado a partir de alquila, arila, alcóxi, arilóxi, tioalquila, tioarila, CN, halo, NR~ 5~R~ 6~, NR~ 4~COR~ 5~, NR~ 4~CONR~ 5~R~ 6~, NR~ 4~CO~ 2~R~ 7~ e NR~ 4~SO~ 2~R~ 7~; R~ 2~ é selecionado a partir de grupos heteroarila que contêm N, O -ou S, em que o grupo heteroarila é ligado através de um átomo de carbono insaturado que é adjacente a um ou dois heteroátomos de N, O ou S, diferentes de grupos heteroarila orto, orto-di-substituídos; - R~ 3~ é selecionado a partir de H, alquila, COR~ 8~, CONR~ 9~R~ 10~, CONR~ 8~NR~ 9~R~ 10~, CO~ 2~R~ 11~ e SO~ 2~R~ 11~; - R~ 4~, R~ 5~ e R~ 6~ são selecionados independentemente a partir de H, alquila e arila ou, quando R~ 5~ e R~ 6~ encontram-se em um grupo NR~ 5~R~ 6~, R~ 5~ e R~ 6~ podem ser ligados para formar um anel heterocíclico; - R~ 7~ é selecionado a partir de alquila e arila; - R~ 8~, R~ 9~ e R~ 10~ são selecionados independentemente a partir de H, alquila e arila, ou R~ 9~ e R~ 10~ podem ser ligados para formar um anel heterocíclico ou, quando R~ 8~, R~ 9~ e R~ 10~ encontram-se em um grupo CONR~ 8~NR~ 9~R~ 10~, R~ 8~ e R~ 9~ podem ser ligados para formar um grupo heterocíclico; e - R~ 11~, é selecionado a partir de alquila e arila; ou um de seus sais ou pró-drogas farmaceuticamente aceitáveis, no tratamento ou prevenção de disfunções em que o bloqueio de receptores de purina, particularmente receptores de adenosina e, mais especificamente, receptores de A~ 2A~, pode ser benéfico, particularmente quando a dita disfunção for uma disfunção do movimento, tal como o mal de Parkinson, ou a dita disfunção for depressão, dificuldade cognitiva ou de memória, dor aguda ou crónica, DHDA ou narcolepsia, ou para neuroproteção de pacientes; compostos da fórmula (I) para USO em terapia; e compostos inovadores da fórmula (I) intrinsecamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100623.8A GB0100623D0 (en) | 2001-01-10 | 2001-01-10 | Chemical compounds IV |
| PCT/GB2002/000076 WO2002055521A1 (en) | 2001-01-10 | 2002-01-10 | Purine derivatives as purinergic receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206561A true BR0206561A (pt) | 2004-06-22 |
Family
ID=9906570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206561-4A BR0206561A (pt) | 2001-01-10 | 2002-01-10 | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7452894B2 (pt) |
| EP (1) | EP1349857B1 (pt) |
| JP (1) | JP4284069B2 (pt) |
| KR (1) | KR20030079945A (pt) |
| CN (1) | CN1617871A (pt) |
| AT (1) | ATE471323T1 (pt) |
| AU (1) | AU2002217331B2 (pt) |
| BR (1) | BR0206561A (pt) |
| CA (1) | CA2433858C (pt) |
| CZ (1) | CZ20031956A3 (pt) |
| DE (1) | DE60236719D1 (pt) |
| GB (1) | GB0100623D0 (pt) |
| HU (1) | HUP0402504A2 (pt) |
| IL (1) | IL156779A0 (pt) |
| MX (1) | MXPA03006163A (pt) |
| NO (1) | NO20033145L (pt) |
| NZ (1) | NZ527249A (pt) |
| PL (1) | PL363172A1 (pt) |
| RU (1) | RU2003124653A (pt) |
| WO (1) | WO2002055521A1 (pt) |
| YU (1) | YU55603A (pt) |
| ZA (1) | ZA200305116B (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1375502B1 (en) * | 2001-04-05 | 2007-06-13 | Sumitomo Chemical Company, Limited | Process for producing 2,6-dihalogenopurine |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| DE10252650A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-Harnstoff-Derivate |
| US7138401B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
| JPWO2005085210A1 (ja) * | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| JP2008534609A (ja) | 2005-03-30 | 2008-08-28 | コンフォーマ・セラピューティクス・コーポレイション | Ｈｓｐ９０阻害剤としてのアルキニルピロロピリミジンおよび関連類似体 |
| US20090023723A1 (en) * | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| CN1947717B (zh) * | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| AR063141A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| RU2681081C2 (ru) | 2007-10-05 | 2019-03-04 | Верастэм, Инк. | Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ, и способ лечения пролиферативных заболеваний |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| WO2010114484A1 (en) | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| PT3446714T (pt) | 2011-06-02 | 2021-06-23 | Univ Louisville Res Found Inc | Nanopartículas conjugadas a um agente antinucleolina |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| PT2840083T (pt) * | 2012-04-17 | 2017-11-08 | Astellas Pharma Inc | Composto heterocíclico aromático bicíclico azotado |
| MX2019005825A (es) * | 2016-11-18 | 2019-07-10 | Procter & Gamble | Composiciones para el tratamiento de telas y metodos para proporcionar un beneficio. |
| US10870816B2 (en) | 2016-11-18 | 2020-12-22 | The Procter & Gamble Company | Fabric treatment compositions having low calculated cationic charge density polymers and fabric softening actives and methods for providing a benefit |
| WO2019039438A1 (ja) * | 2017-08-21 | 2019-02-28 | 国立大学法人三重大学 | 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置 |
| CN107903274A (zh) * | 2017-12-28 | 2018-04-13 | 窦玉玲 | 一种胺类化合物及其在抗肿瘤药物中的应用 |
| CN114025758A (zh) * | 2019-07-01 | 2022-02-08 | 钱立刚 | P2x7r拮抗剂 |
| KR20210061202A (ko) * | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| US11787775B2 (en) * | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US11806350B2 (en) | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
| CN116589464B (zh) * | 2022-02-14 | 2025-10-31 | 上海科技大学 | 嘧啶并环类化合物、其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3630997A (en) * | 1970-05-04 | 1971-12-28 | Paul M Craven | Curable epoxy resin compositions and method of preparing same |
| US5064745A (en) * | 1988-02-25 | 1991-11-12 | Mitsubishi Paper Mills, Ltd. | Method for making lithographic printing plate |
| US5403932A (en) * | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| US5968989A (en) * | 1991-12-18 | 1999-10-19 | The Salk Institute For Biological Studies | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| DE4330735A1 (de) * | 1993-09-10 | 1995-03-16 | Wacker Chemie Gmbh | Hydrophile Gruppen aufweisende Organopolysiloxane |
| US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| SK179899A3 (en) | 1997-07-03 | 2001-12-03 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| WO1999026627A1 (en) * | 1997-11-26 | 1999-06-03 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| US6579868B1 (en) | 1998-01-05 | 2003-06-17 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| JPH11279193A (ja) * | 1998-03-24 | 1999-10-12 | Akira Matsuda | アデノシン誘導体 |
| GB9819382D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| NZ516260A (en) | 1999-07-02 | 2004-08-27 | Eisai Co Ltd | Fused imidazole compounds and remedies for diabetes mellitus |
| CN1441773A (zh) * | 2000-04-26 | 2003-09-10 | 沃尼尔·朗伯公司 | 作为亚型选择性nmda受体拮抗剂的环己胺衍生物 |
| US6903238B2 (en) * | 2001-12-13 | 2005-06-07 | Wyeth | Substituted indenones as estrogenic agents |
| US6946005B2 (en) * | 2002-03-27 | 2005-09-20 | L'oreal S.A. | Pyrrolidinyl-substituted para-phenylenediamine derivatives substituted with a cationic radical, and use of these derivatives for dyeing keratin fibers |
| DE10326303A1 (de) * | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
| RU2007130896A (ru) * | 2005-01-14 | 2009-02-20 | Дженелэбс Текнолоджиз, Инк. (Us) | Индольные производные для лечения вирусных инфекций |
| JP5190364B2 (ja) * | 2005-09-09 | 2013-04-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状ペプチドの調製の為の閉環メタセシス工程 |
| EP1965805B1 (en) * | 2005-11-25 | 2009-12-02 | Galapagos SAS | Urea derivatives useful as calcium receptor modulators |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| RU2009105837A (ru) * | 2006-07-20 | 2010-08-27 | СмитКлайн Бичем Копэрейшн (US) | Полициклические противовирусные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусной инфекции с ее помощью и названные соединения для изготовления лекарственных средств |
-
2001
- 2001-01-10 GB GBGB0100623.8A patent/GB0100623D0/en not_active Ceased
-
2002
- 2002-01-10 HU HU0402504A patent/HUP0402504A2/hu unknown
- 2002-01-10 JP JP2002556190A patent/JP4284069B2/ja not_active Expired - Fee Related
- 2002-01-10 NZ NZ527249A patent/NZ527249A/xx unknown
- 2002-01-10 AT AT02729444T patent/ATE471323T1/de not_active IP Right Cessation
- 2002-01-10 DE DE60236719T patent/DE60236719D1/de not_active Expired - Lifetime
- 2002-01-10 KR KR10-2003-7009241A patent/KR20030079945A/ko not_active Withdrawn
- 2002-01-10 RU RU2003124653/04A patent/RU2003124653A/ru not_active Application Discontinuation
- 2002-01-10 EP EP02729444A patent/EP1349857B1/en not_active Expired - Lifetime
- 2002-01-10 CN CNA028062582A patent/CN1617871A/zh active Pending
- 2002-01-10 MX MXPA03006163A patent/MXPA03006163A/es unknown
- 2002-01-10 PL PL02363172A patent/PL363172A1/xx not_active Application Discontinuation
- 2002-01-10 AU AU2002217331A patent/AU2002217331B2/en not_active Ceased
- 2002-01-10 US US10/250,941 patent/US7452894B2/en not_active Expired - Fee Related
- 2002-01-10 BR BR0206561-4A patent/BR0206561A/pt not_active Application Discontinuation
- 2002-01-10 CA CA2433858A patent/CA2433858C/en not_active Expired - Fee Related
- 2002-01-10 IL IL15677902A patent/IL156779A0/xx unknown
- 2002-01-10 WO PCT/GB2002/000076 patent/WO2002055521A1/en not_active Ceased
- 2002-01-10 CZ CZ20031956A patent/CZ20031956A3/cs unknown
- 2002-01-10 YU YU55603A patent/YU55603A/sh unknown
-
2003
- 2003-07-01 ZA ZA200305116A patent/ZA200305116B/xx unknown
- 2003-07-09 NO NO20033145A patent/NO20033145L/no not_active Application Discontinuation
-
2006
- 2006-07-19 US US11/488,750 patent/US20060270691A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL363172A1 (en) | 2004-11-15 |
| ZA200305116B (en) | 2004-07-01 |
| KR20030079945A (ko) | 2003-10-10 |
| JP4284069B2 (ja) | 2009-06-24 |
| CA2433858C (en) | 2010-12-14 |
| DE60236719D1 (de) | 2010-07-29 |
| CA2433858A1 (en) | 2002-07-18 |
| YU55603A (sh) | 2006-05-25 |
| EP1349857A1 (en) | 2003-10-08 |
| NZ527249A (en) | 2005-04-29 |
| RU2003124653A (ru) | 2005-01-10 |
| US7452894B2 (en) | 2008-11-18 |
| MXPA03006163A (es) | 2003-09-16 |
| ATE471323T1 (de) | 2010-07-15 |
| GB0100623D0 (en) | 2001-02-21 |
| US20040102459A1 (en) | 2004-05-27 |
| CN1617871A (zh) | 2005-05-18 |
| WO2002055521A1 (en) | 2002-07-18 |
| NO20033145D0 (no) | 2003-07-09 |
| AU2002217331B2 (en) | 2006-06-29 |
| EP1349857B1 (en) | 2010-06-16 |
| US20060270691A1 (en) | 2006-11-30 |
| HUP0402504A2 (hu) | 2005-04-28 |
| NO20033145L (no) | 2003-09-09 |
| CZ20031956A3 (cs) | 2003-11-12 |
| JP2004517874A (ja) | 2004-06-17 |
| IL156779A0 (en) | 2004-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0206561A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
| BR0206559A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
| BR0007424A (pt) | Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto | |
| GB0100622D0 (en) | Chemical compounds V111 | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| BR0010391A (pt) | Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| BR0213452A (pt) | Derivados de piperazina com atividade antagonista receptora de ccr1 | |
| AR022687A1 (es) | Derivados de 2,3,4,4a-tetrahidro-1h-pirazino[1,2-a] quinoxalin-5(6h)ona, una composicion farmaceutica y el uso de los mismos para la manufactura de losmedicamentos. | |
| TW200517109A (en) | Substituted pyridinones | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| ATE383360T1 (de) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs | |
| GB0100620D0 (en) | Chemical cokpounds V | |
| DK1412354T3 (da) | Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter | |
| TW200502230A (en) | Dual nk1/nk3 derivatives | |
| BR0317705A (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças ou condições, e, processo para a preparação de compostos | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| DE60313478D1 (de) | N-substituierte hydromorphone und ihre anwendung | |
| AP1456A (en) | Pharmaceutical agents for the treatment of parkinson's disease, ADHD and microadenomas. | |
| MXPA02001571A (es) | Metodo de tratamiento para el cancer. | |
| MA32057B1 (fr) | Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique | |
| ATE556712T1 (de) | A2a antagonisten zur behandlung von motorischen störungen | |
| BR0010693A (pt) | Derivados azaindol para tratamento de depressão | |
| BRPI0719869A2 (pt) | Composto ou um sal do mesmo, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono em uma mamífero, e, uso do composto. | |
| BR0317289A (pt) | Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |